Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190946 | 0.87 | LMNA (0.59) | LMNAKMT2ANFE2L2TDP1HPGD | |
| SCHEMBL4378985 | 0.87 | LMNA (0.59) | LMNAKMT2ANFE2L2TDP1HPGD | |
| SCHEMBL14218034 | 0.84 | TDP1 (0.61) | LMNAKMT2ATDP1HPGDL3MBTL1 | |
| SCHEMBL29913258 | 0.83 | NFE2L2 (0.64) | LMNAKMT2ANFE2L2HPGDL3MBTL1 | |
| SCHEMBL14190940 | 0.81 | KMT2A (0.61) | LMNAKMT2ANFE2L2HPGDL3MBTL1 | |
| SCHEMBL4382984 | 0.81 | KMT2A (0.61) | LMNAKMT2ANFE2L2HPGDL3MBTL1 | |
| SCHEMBL3769341 | 0.80 | L3MBTL1 (0.53) | LMNAKMT2ANFE2L2TDP1HPGD | |
| SCHEMBL3769345 | 0.80 | L3MBTL1 (0.53) | LMNAKMT2ANFE2L2TDP1HPGD | |
| SCHEMBL4386306 | 0.80 | KMT2A (0.60) | LMNAKMT2ANFE2L2HPGDL3MBTL1 | |
| SCHEMBL14190925 | 0.80 | KMT2A (0.60) | LMNAKMT2ANFE2L2HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | LMNA 4304/4885KMT2A 295/4885NFE2L2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.